DRG Market Assessment reports

In the past decade, the TNF-α inhibitors Humira (AbbVie) and Enbrel (Amgen) and the IL-12/23 inhibitor Stelara (Janssen) have been leading the U.S. psoriasis biologics market. However, the recent…

The psoriasis therapy market has become increasingly lucrative owing to the growing use of biologics. The dominance of the tumor necrosis factor (TNF)-alpha inhibitors and interleukin (IL)-12/23…

Pustular psoriasis is a rare subtype of psoriasis, typically seen as pustules that erupt generally across the body (generalized pustular psoriasis [GPP]) or are localized, typically on the hands…

MARKET OUTLOOK In the past decade, tumor necrosis factor-alpha (TNF-α) inhibitors, including AbbVie’s Humira and Amgen’s Enbrel, and Janssen’s interleukin IL-12/23 inhibitor Stelara have…

MARKET OUTLOOK In the past decade, AbbVie’s Humira and Amgen’s Enbrel tumor necrosis factor-alpha (TNF-α) inhibitors and Janssen’s interleukin (IL)-12/23 inhibitor Stelara have been…

In the past decade, the TNF-α inhibitors Humira (AbbVie) and Enbrel (Amgen) and the IL-12/23 inhibitor Stelara (Janssen) have been leading the U.S. psoriasis biologics market. However, the recent…

With a drug-treated population of more than 4 million people in the United States and EU5, the psoriasis market has been a lucrative space for drug developers, resulting in a plethora of approved…

MARKET OUTLOOK Despite similarities between adult psoriasis and pediatric psoriasis, pediatric psoriasis presents a challenge for patients seeking effective long-term therapy. Thetreatments…

MARKET OUTLOOK Increasingly, moderate-to-severe psoriasis represents an increasingly lucrative market for targeted systemic treatments. Although adult psoriasis and pediatric psoriasis are…

The psoriasis therapy market has become increasingly lucrative owing to the growing use of biologics. The dominance of the tumor necrosis factor (TNF)-alpha inhibitors and interleukin (IL)-12/23…

In the past decade, TNF-α inhibitors Humira (AbbVie) and Enbrel (Amgen), as well as Janssen’s IL-12/23 inhibitor Stelara, have been leading the U.S. psoriasis biologics market. However, the…

The psoriasis market has become increasingly lucrative owing to the growing use of biologics in the moderate to severe patient population, who cannot be adequately controlled with topical agents…